

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: RFA2/20 - Risk Factors for Atherosclerosis

Deadline: 28.08.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(111) Cholesterol</b>					297							297	281	95%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		7,81	0,33	4,2	297	CVP	7,81	0,046	8%	7,18	8,44	297	286	96%
(1) Enzyme method CHOD-PAP		7,81	0,33	4,2	297	0						297		
<b>Sample B</b>		3,66	0,14	3,7	297	CVP	3,66	0,019	8%	3,36	3,96	297	289	97%
(1) Enzyme method CHOD-PAP		3,66	0,14	3,7	297	0						297		
<b>(112) Triglycerides</b>					297							297	293	99%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		2,26	0,069	3,0	297	CVP	2,26	,0098	15%	1,92	2,6	297	294	99%
(1) Photometric enzyme (GPO-PAP)		2,26	0,069	3,1	283	0						283		
(2) Enzymatic UV method		2,25	0,071	3,1	14	0						14		
<b>Sample B</b>		1,09	0,04	3,7	297	CVP	1,09	,0057	15%	0,926	1,26	297	295	99%
(1) Photometric enzyme (GPO-PAP)		1,09	0,04	3,6	283	0						283		
(2) Enzymatic UV method		1,08	0,046	4,2	14	0						14		
<b>(113) Cholesterol HDL</b>					298							298	293	98%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		2,14	0,12	5,7	298	CVP	2,14	0,017	15%	1,81	2,47	298	296	99%
(2) Direct determination		2,14	0,12	5,7	294	0						294		
Other					4	0						4		
<b>Sample B</b>		0,997	0,046	4,6	298	CVP	0,997	,0066	15%	0,847	1,15	298	294	99%
(2) Direct determination		0,997	0,046	4,6	294	0						294		
Other					4	0						4		
<b>(114) Apolipoprotein AI</b>					87							87	84	97%
— Samples and groups	[g/L]													
<b>Sample A</b>		2,31	0,19	8,4	87	CVP	2,31	0,051	21%	1,82	2,8	87	86	99%
(2) Immunoturbidimetry		2,30	0,20	8,6	78	0						78		
(3) Immunonephelometry		2,32	0,11	4,8	9	0						9		
<b>Sample B</b>		1,10	0,067	6,1	87	CVP	1,1	0,018	21%	0,869	1,34	87	85	98%
(2) Immunoturbidimetry		1,09	0,071	6,5	78	0						78		
(3) Immunonephelometry		1,13	0,037	3,3	9	0						9		
<b>(115) Apolipoprotein B</b>					102							102	101	99%
— Samples and groups	[g/L]													
<b>Sample A</b>		1,45	0,10	7,1	102	CVP	1,45	0,025	18%	1,18	1,72	102	102	100%
(2) Immunoturbidimetry		1,45	0,10	7,1	94	0						94		
(3) Immunonephelometry		1,45	0,10	7,2	8	0						8		
<b>Sample B</b>		0,700	0,039	5,6	102	CVP	0,7	,0095	18%	0,574	0,826	102	101	99%
(2) Immunoturbidimetry		0,699	0,04	5,7	94	0						94		
(3) Immunonephelometry		0,712	0,033	4,6	8	0						8		
<b>(116) Cholesterol LDL (calculation)</b>					138							138	126	91%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		4,60	0,27	5,8	138	CVP	4,6	0,056	15%	3,91	5,29	138	129	93%
(0) Not specified		4,60	0,27	5,8	138	0						138		
<b>Sample B</b>		2,16	0,14	6,3	138	CVP	2,16	0,028	15%	1,83	2,49	138	131	95%
(0) Not specified		2,16	0,14	6,3	138	0						138		
<b>(118) Cholesterol LDL (direct determ.)</b>					215							215	210	98%
— Samples and groups	[mmol/L]													
<b>Sample A</b>		4,80	0,40	8,4	215	CVP	4,8	0,067	15%	4,08	5,52	215	211	98%
(0) Not specified		4,80	0,40	8,4	215	0						215		
<b>Sample B</b>		2,27	0,16	7,0	215	CVP	2,27	0,027	15%	1,92	2,62	215	213	99%
(0) Not specified		2,27	0,16	7,0	215	0						215		
<b>(117) Lipoprotein (a) [g/L]</b>					30							30	28	93%
— Samples and groups	[g/L]													
<b>Sample A</b>		0,400	0,033	8,3	30	CVP	0,4	0,015	32%	0,272	0,528	30	28	93%
(2) Immunoturbidimetry		0,399	0,025	6,2	25	0						25		
Other					5	0						5		
<b>Sample B</b>		0,204	0,021	10	30	CVP	0,204	,0094	32%	0,138	0,27	30	30	100%
(2) Immunoturbidimetry		0,204	0,017	8,2	25	0						25		
Other					5	0						5		

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

## EQA round: RFA2/20 - Risk Factors for Atherosclerosis

Deadline: 28.08.2020

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability						N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(119) Lipoprotein (a) [nmol/L]</b>	[nmol/L]				27								27	25	93%
----- Samples and groups -----															
<b>Sample A</b>															
(2) Immunoturbidimetry		79,6	3,8	4,8	27	CVP	79,6	1,8	20%	63,6	95,6		27	26	96%
Other		79,5	3,9	4,9	26	0							26		
					1	0							1		
<b>Sample B</b>															
(2) Immunoturbidimetry		38,0	3,3	8,7	27	<sup>1x3</sup> CVP	38	1,6	20%	30,4	45,6		27	25	93%
Other		38,1	3,4	8,9	26	0							26		
					1	0							1		

st\_kn\_p

End of report

Printed: 07.09.2020